Orthofix Medical Inc. provided revenue guidance for the first quarter, second quarter and third quarter of 2024. The company expected first quarter and second quarter revenue to be slightly below full year growth guidance range due to the timing of stocking orders in 2023. Additionally, the company expected third quarter to reflect the highest year-over-year growth rate due to disruption in prior year as closed the quarter.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12.87 USD | +2.39% | +2.06% | -4.53% |
Jun. 18 | Orthofix Medical Inc. Appoints Aviva Mcpherron as President of Global Operations and Quality | CI |
Jun. 11 | Orthofix Names Julie Dewey Chief Investor Relations and Communications Officer | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-4.53% | 483M | |
-3.19% | 105B | |
-4.14% | 67.55B | |
+15.49% | 46.71B | |
-6.00% | 46.39B | |
+4.77% | 40.68B | |
+22.10% | 31.63B | |
+11.75% | 24.35B | |
-8.53% | 23.46B | |
-12.33% | 21.95B |
- Stock Market
- Equities
- OFIX Stock
- News Orthofix Medical Inc.
- Orthofix Medical Inc. Provides Revenue Guidance for the First Quarter, Second Quarter and Third Quarter of 2024